CLDN2 Antibody

What is Claudin-2 (CLDN2) and why is it important in research?

Claudin-2 is a protein encoded by the CLDN2 gene in humans with a reported amino acid length of 230 and an expected molecular mass of 24.5 kDa. It is a well-defined component of cellular tight junctions that regulates paracellular permeability . Research importance stems from its involvement in various biological processes, including its role as a negative regulator of RHOA signaling and its significant upregulation in several pathological conditions, particularly colorectal cancer (CRC) . Understanding CLDN2 function provides insights into epithelial barrier physiology, cancer progression mechanisms, and potential therapeutic targets for diseases characterized by barrier dysfunction.

What types of CLDN2 antibodies are available for research?

Researchers can access multiple types of CLDN2 antibodies with varying characteristics:

When selecting antibodies, researchers should consider specific epitope targeting, host species compatibility with experimental systems, and validated applications for each antibody .

How is CLDN2 protein structure related to antibody epitope selection?

CLDN2 protein contains four transmembrane domains, two extracellular loops, and intracellular N- and C-termini. Most commercially available antibodies target either the C-terminal domain (AA 200-227) or specific regions within the protein (AA 29-81, AA 30-230, AA 135-164) . The epitope selection significantly impacts experimental applications:

• Antibodies targeting extracellular loops are suitable for live cell studies or blocking experiments

• C-terminal targeting antibodies work well for Western blotting and fixed-cell applications

• N-terminal antibodies may have different accessibility depending on experimental conditions

Researchers should match epitope selection to experimental goals, considering that conformational changes or protein interactions may mask certain epitopes in native conditions .

What are the validated applications for CLDN2 antibodies?

CLDN2 antibodies have been validated for multiple applications with specific methodological considerations:

• Western Blotting (WB): Recommended dilutions typically range from 1:1000-1:5000. CLDN2 appears as a band at approximately 24.5 kDa, though post-translational modifications may cause slight variations in mobility .

• Immunohistochemistry (IHC): Both paraffin-embedded and frozen sections can be used. Optimization of antigen retrieval methods is critical, with citrate buffer at pH 6.0 commonly used for CLDN2 detection .

• Immunofluorescence (IF): Recommended dilutions range from 1:50-1:200. Researchers should be aware that CLDN2 localizes primarily to tight junctions, appearing as a characteristic "chicken wire" pattern in epithelial monolayers .

• ELISA: CLDN2 antibodies can be used in standard ELISA protocols, though specificity validation through appropriate controls is essential .

Each application requires specific optimization steps and controls to ensure reliable results.

How should researchers validate CLDN2 antibody specificity?

Validation of CLDN2 antibody specificity requires a multi-faceted approach:

• Positive and negative cell/tissue controls: Use cells/tissues known to express high levels of CLDN2 (e.g., HT29 colorectal cancer cells) versus those with low expression (e.g., HCT116 cells) .

• Genetic validation: Use CLDN2 knockout or knockdown models created through CRISPR-Cas9 or siRNA approaches, as demonstrated in studies where "CLDN2 was knocked out in CLDN2-high HT29 cells through CRISPR-Cas9" .

• Peptide competition assays: Pre-incubate antibody with excess recombinant CLDN2 protein to confirm binding specificity.

• Cross-reactivity assessment: Test against related claudin family members, particularly those with sequence homology to CLDN2.

• Western blot verification: Confirm detection of a single band at the expected molecular weight (24.5 kDa) .

Researchers should document that "Western blot of equally loaded cell lysates and recombinant CLDN2-GST protein was probed with anti-CLDN2 antibody" to establish specificity .

What are the key considerations for immunofluorescence studies with CLDN2 antibodies?

When conducting immunofluorescence with CLDN2 antibodies, researchers should consider:

• Fixation method: Paraformaldehyde (4%) fixation preserves CLDN2 localization at tight junctions, while methanol can disrupt membrane structure.

• Permeabilization: Mild detergents (0.1-0.2% Triton X-100) allow antibody access to intracellular domains without disrupting membrane proteins.

• Co-localization markers: Include other tight junction proteins (ZO-1, occludin) for verification of proper localization.

• Control staining: Include CLDN2 knockout/knockdown cells processed identically to experimental samples.

• Optimal dilution: Start with manufacturer's recommendations (typically 1:50-1:200) and optimize for each experimental system .

• Signal amplification: Consider tyramide signal amplification for low-abundance detection.

Studies have successfully used these approaches to visualize changes in tight junction morphology following CLDN2 manipulation, revealing that "in cells transfected with CLDN-2 siRNA stress fibers were thicker and more numerous" .

How can CLDN2 antibodies be used to study tight junction protein complexes?

CLDN2 antibodies enable sophisticated analysis of tight junction complexes through:

• Co-immunoprecipitation (Co-IP): CLDN2 antibodies can pull down intact protein complexes to identify interaction partners. Studies have used this approach to demonstrate that "CLDN2 depletion promoted CLDN2/ZO1/ZONAB complex dissociation" . Key methodological considerations include:

  • Gentle cell lysis to preserve protein-protein interactions

  • Antibody selection targeting regions not involved in protein-protein binding

  • Controls using IgG from the same species as the CLDN2 antibody

• Proximity ligation assay (PLA): This technique visualizes protein interactions within 40nm distance, useful for confirming CLDN2 interactions with ZO-1, ZO-2, and ZONAB in intact cells.

• FRET/FLIM analysis: When combined with fluorescently-tagged junction proteins, CLDN2 antibodies can help establish physical proximity within the nanometer range.

• Chromatin immunoprecipitation (ChIP): For nuclear ZONAB studies following its dissociation from CLDN2 complexes.

These approaches have revealed critical insights about the "CLDN2/ZO1/ZONAB-NDRG1 axis in CRC by regulating the expression of EMT-related genes and CDKIs" .

What is the role of CLDN2 in RHOA signaling and how can antibodies help investigate this pathway?

CLDN2 has been identified as "a negative regulator of RHOA signaling" , with significant implications for cellular processes. To investigate this pathway:

• Immunofluorescence co-localization: CLDN2 antibodies combined with RHOA staining can reveal spatial relationships during signaling events.

• Active RHOA detection: "Active RHOA-specific antibody to stain kidney sections obtained from WT or CLDN-2 KO mice" demonstrates increased RHOA activity in CLDN2-deficient tissues .

• Phospho-specific detection: Combine CLDN2 antibodies with phospho-MLC antibodies to assess downstream RHOA signaling effects, as "CLDN-2 silencing caused a well-detectable increase in the phosphorylation of both MLC isoforms" .

• GEF-H1 phosphorylation assessment: CLDN2 manipulation affects "GEF-H1 phosphorylation at Ser-885, which was shown to increase GEF-H1 activity" .

• F-actin organization: CLDN2 antibody staining combined with phalloidin reveals that CLDN2 silencing results in cells where "stress fibers were thicker and more numerous" .

These methodological approaches have established that "loss of CLDN-2 causes RHOA-dependent decrease in proliferation and promotes fibrogenic epithelial reprogramming" .

How can CLDN2 antibodies be applied in cancer research?

CLDN2 antibodies have diverse applications in cancer research:

• Expression profiling: IHC with CLDN2 antibodies can assess expression levels across tumor tissues, revealing that "CLDN2 expression was significantly elevated in CRC patients and was also closely related to tumour metastasis and patient survival" .

• Prognostic marker validation: Correlating CLDN2 expression with clinical outcomes using tissue microarrays.

• Mechanistic studies: Investigating how CLDN2 affects cancer cell behavior through its interactions with signaling pathways.

• Therapeutic target assessment: Evaluating CLDN2 as a potential target by using blocking antibodies against extracellular domains.

• Functional validation: Combining CLDN2 antibody-based detection with genetic manipulation through "CLDN2 knockout in CLDN2-high HT29 cells through CRISPR-Cas9" or overexpression in "CLDN2-low HCT116 cells using plenti-CMV-EGFP plasmid" .

These applications have established that "CLDN2 upregulation inhibited NDRG1 expression, resulting in epithelial–mesenchymal transition (EMT) activation and decreased expression of cyclin-dependent kinase inhibitors (CDKIs)" .

What are common challenges in CLDN2 antibody-based detection and how can they be addressed?

Researchers often encounter several challenges when working with CLDN2 antibodies:

• Non-specific binding: Some commercial antibodies may cross-react with other claudin family members due to sequence homology.

  • Solution: Validate antibody specificity using CLDN2 knockout controls and peptide competition assays.

• Inconsistent immunolabeling: Variable staining patterns can occur across different tissue preparations.

  • Solution: Standardize fixation protocols and optimize antigen retrieval methods for each tissue type.

• Misleading antibody validation: Published antibodies may not correctly identify intended antigens in formalin-fixed tissues.

  • Solution: Perform tiered validation approaches as described: "This assay underwent a novel tiered approach of validation to establish that it was fit-for-purpose, and suitable for clinical deployment" .

• Membrane protein extraction difficulties: CLDN2's tight association with membrane fractions can complicate protein isolation.

  • Solution: Use specialized membrane protein extraction buffers containing appropriate detergents (e.g., 1% Triton X-100 or 0.5% SDS).

• Epitope masking in complex tissues: Protein-protein interactions may block antibody access.

  • Solution: Test multiple antibodies targeting different epitopes and optimize antigen retrieval.

These challenges underscore the importance of proper validation: "we have applied a strategy for identifying target-specific antibodies in formalin fixed biopsy samples and highlighted that (published) antibodies may not correctly identify the intended antigen" .

How can researchers reconcile conflicting data from different CLDN2 antibodies?

When facing contradictory results from different CLDN2 antibodies, researchers should:

• Compare epitope recognition sites: Different antibodies may target distinct regions of CLDN2 that are differentially accessible depending on protein conformation or interactions.

• Evaluate clonality differences: Polyclonal antibodies provide broader epitope recognition but potentially more background, while monoclonal antibodies offer higher specificity but may miss certain protein variants.

• Consider species cross-reactivity: Antibodies raised against human CLDN2 may have varying affinity for mouse or rat CLDN2 due to sequence variations.

• Assess post-translational modifications: Some antibodies may preferentially recognize modified forms of CLDN2.

• Implement orthogonal detection methods: Supplement antibody-based detection with mRNA analysis or mass spectrometry.

• Perform side-by-side comparisons: Test multiple antibodies simultaneously under identical conditions.

• Genetic validation: Ultimately, CLDN2 knockout/knockdown experiments provide the most definitive validation of antibody specificity.

This systematic approach helps resolve discrepancies and ensures reliable data interpretation across different experimental systems.

What controls should be included when quantifying CLDN2 expression in research samples?

Proper quantification of CLDN2 expression requires rigorous controls:

• Positive and negative tissue controls: Include tissues with established CLDN2 expression patterns. For example, normal proximal tubules in kidney express high CLDN2 levels, while distal tubules have minimal expression .

• Loading controls: For Western blotting, include housekeeping proteins (β-actin, GAPDH) and normalize band intensities appropriately.

• Genetic modification controls: Include "CLDN2 knockout in CLDN2-high HT29 cells through CRISPR-Cas9" or "CLDN2-low HCT116 cells" with overexpression .

• Recombinant protein standards: Include "recombinant CLDN2-GST protein" to create standard curves for quantification .

• Technical replicates: Multiple measurements across independent experiments with appropriate statistical analysis.

• Comparison to established metrics: In disease studies, correlate CLDN2 expression with established metrics, such as "the Geboes score" for inflammatory conditions .

• mRNA validation: Complement protein detection with qPCR or in situ hybridization for CLDN2 mRNA.

These controls enable accurate quantification and meaningful comparison across experimental conditions.

How might CLDN2 antibodies be used in developing potential therapeutic approaches?

CLDN2 antibodies could facilitate therapeutic development through:

• Target validation: Confirming CLDN2 as a druggable target in diseases where it is dysregulated, particularly in cancers where "CLDN2 has a significant contribution to CRC proliferation and migration/invasion" .

• Therapeutic antibody development: Engineering antibodies against CLDN2 extracellular domains to potentially block its function in pathological conditions.

• Companion diagnostics: Using validated CLDN2 antibodies to identify patients most likely to respond to CLDN2-targeting therapies.

• Antibody-drug conjugates: Leveraging CLDN2's selective expression to deliver cytotoxic agents specifically to CLDN2-overexpressing cancer cells.

• Response biomarker: Monitoring CLDN2 expression changes during treatment to assess efficacy of therapies targeting related pathways.

These approaches support the notion that "CLDN2/ZO1/ZONAB-NDRG1 axis could serve as a promising therapeutic target for CRC" .

What novel methodological approaches are being developed for CLDN2 detection?

Emerging methods for CLDN2 detection include:

• In situ hybridization assays: As described in the research where "an in situ hybridization assay was developed" with "a novel tiered approach of validation" .

• Mass spectrometry-based quantification: Absolute quantification of CLDN2 protein levels using isotope-labeled peptide standards.

• Single-cell analysis: Combining CLDN2 antibodies with single-cell technologies to reveal expression heterogeneity within tissues.

• Spatial transcriptomics integration: Correlating CLDN2 protein localization with spatial gene expression patterns in tissues.

• Live-cell imaging: Using non-perturbing antibody fragments to track CLDN2 dynamics in living systems.

• Multiplex imaging: Simultaneous detection of CLDN2 along with multiple tight junction components and signaling molecules.

These advanced methodologies will provide deeper insights into CLDN2 biology and pathological significance across various disease contexts.